menu search

New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa
PITTSBURGH, Dec. 14, 2022 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that data from the pivotal Phase 3 (GEM-3) trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa (DEB) have been published here in the […] The post New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epider... Read More
Posted: Dec 14 2022, 22:00
Author Name: forextv
Views: 102848

Search within

Pages Search Results: